DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/wqz435/china) has announced the addition of the "China Pharmaceuticals & Health Care Industry 2H12" report to their offering.
China: Pharmaceuticals & Health Care covers the sector overview, market size and value, social secuity and health insurance, health care infrastructure, overview of the pharmaceutical industry, regulations and policies.
It also covers the market trends and outlook, social health care insurance system, traditional Chinese medicine, over-the-counter and vaccines, plus the profile, comparative matrix and SWOT analysis of the industry leading players:
- Shanghai Pharmaceuticals Holding Co. Ltd.
- China National Accord Medicines Corp. Ltd.
- Harbin Pharmaceutical Group Co. Ltd.
- Yunnan Baiyao Group Co. Ltd.
- Huadong Medicine Co. Ltd.
Executive Summary
In China, government spending on health care grew at a CAGR of 18.80% between 2004 and 2011. Nevertheless, public health care expenditure of total GDP in China still trails many advanced economies like the United States, Canada and Germany.
Health care spending per capita in urban and rural China reached RMB 534 and RMB 261 respectively during the first six months in 2012. Social security medical fund and private health insurance premiums have risen rapidly over the last decade. The number of retirees insured under the medical fund in urban areas reached 62.8 million by the end of 2011.
Revenues from the Chinese pharmaceutical industry grew from RMB 520.2bn in 2006 to RMB 1.53tn in 2011, representing a CAGR of 24.02%. Chemical drugs preparation, Chinese prepared medicine and chemical medicine were the three largest product categories in the pharmaceutical industry in the first half in 2012. Total sales of Chinese prepared and herb medicines topped nearly RMB 220bn during the same period.
For more information visit http://www.researchandmarkets.com/research/wqz435/china